AZNAstraZenecaRunning, no new patients
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency
Hormone-Sensitive Prostate Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 1,012 (final count)
- Started
- Jul 13, 2020
- Main results expected
- Oct 7, 2024
- Fully finished
- Mar 31, 2027
- Results posted
- Sep 10, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Radiographic Progression-free Survival (rPFS)
Measured over: Tumor assessments every 16 weeks from randomisation until radiographic progression assessed by the investigator. The timing of the Primary analysis DCO for rPFS is approximately 49 months from the first subject randomized
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04493853 · record last updated 2026-09-10 · checked 2026-11-09 15:47 UTC